Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis by Kim, Hae-Rim et al.
RESEARCH ARTICLE Open Access
Macrophage migration inhibitory factor enhances
osteoclastogenesis through upregulation of
RANKL expression from fibroblast-like
synoviocytes in patients with rheumatoid arthritis
Hae-Rim Kim
1†, Kyoung-Woon Kim
2†, Hong Geun Jung
3, Kwang-Sup Yoon
3, Hye-Jwa Oh
4, Mi-La Cho
4*†,
Sang-Heon Lee
1*†
Abstract
Introduction: Macrophage migration inhibitory factor (MIF) is one of key regulators in acute and chronic immune-
inflammatory conditions including rheumatoid arthritis (RA). We examined the effect of MIF on osteoclastogenesis,
which is known to play a crucial role in bone destruction in RA.
Methods: The concentration of MIF and receptor activator of nuclear factor-B ligand (RANKL) in the synovial fluid was
measured by ELISA. MIF-induced RANKL expression of RA synovial fibroblasts was determined by real-time PCR and
western blot. Osteoclastogenesis was analyzed in culture of human peripheral blood mononuclear cells (PBMC) with MIF.
Osteoclastogenesis was also determined after co-cultures of rhMIF-stimulated RA synovial fibroblasts with human PBMC.
Results: Synovial fluid MIF concentration in RA patients was significantly higher than in osteoarthritis (OA) patients.
The concentration of RANKL correlated with that of MIF in RA synovial fluids (r = 0.6, P < 0.001). MIF stimulated the
expression of RANKL mRNA and protein in RA synovial fibroblasts, which was partially reduced by blocking of
interleukin (IL)-1b. Osteoclasts were differentiated from PBMC cultures with MIF and M-CSF, even without RANKL.
Osteoclastogenesis was increased after co-culture of MIF-stimulated RA synovial fibroblasts with PBMC and this
effect was diminished by RANKL neutralization. Blocking of PI3 kinase, p38 MAP kinase, JAK-2, NF-B, and AP-1 also
led to a marked reduction in RANKL expression and osteoclastogenesis.
Conclusions: The interactions among MIF, synovial fibroblasts, osteoclasts, RANKL, and IL-1b have a close
connection in osteoclastogenesis and they could be a potential gateway leading to new therapeutic approaches in
treating bone destruction in RA.
Introduction
Macrophage migration inhibitory factor (MIF) plays a
crucial role in rheumatoid arthritis (RA) pathogenesis,
linking the innate and adaptive immune responses
[1,2]. As well as its role in inflammatory responses,
MIF takes part in the destructive process in RA. In RA
joint destruction, matrix metalloproteinases (MMP) are
thought to play an important role in synovial invasion
[3,4]. Various MMPs are upregulated in RA synovial
fluid and synovium [4-6], and MIF upregulates MMP-
1, MMP-2, and MMP-3 expression in RA synovial
fibroblasts [4,6]. MIF also induces MMP-9 and MMP-
13 in rat osteoblasts [7]. Besides the induction of
MMPs, MIF participates indirectly in joint destruction
by promoting angiogenesis in RA synovial fibroblasts
[8] and inducing many osteoclast (OC)-inducing mole-
c u l e ss u c ha sT N F - a,I L - 1 ,I L - 6 ,a n dp r o s t a g l a n d i nE 2
(PGE2) [1,2,9,10].
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i n d u c e db o n el o s sa n dM I Ft r a n s g e n i cm i c eh a v eh i g h -
turnover osteoporosis, suggesting that MIF could mediate
bone resorption during bone remodeling and balance
[11,12]. MIF also upregulates the expression of receptor
activator of nuclear factor-B ligand (RANKL) mRNA in
murine osteoblasts. MIF has no effect on bone formation,
indicating that it might play a role in the physiological or
pathological metabolism of bone, especially in bone
resorption [12]. However, a recent study suggests that
MIF inhibits osteoclastogenesis, based on the result that
MIF inhibits OC formation in murine bone marrow
(BM) cultures in the presence of RANKL. BM cells from
MIF knockout mice had an increased capacity to form
OC, and MIF knockout mice had decreased trabecular
bone volume with low turnover [13].
To date, the effects of MIF on osteoclastogenesis have
not been studied in the context of human disease sys-
tems. Two clinical studies suggest that MIF might be
involved in joint destruction in RA patients. Greater cir-
culating MIF levels correlate with more severe radio-
graphic joint damage [14], and the MIF concentration of
synovial fluid is significantly higher in RA patients with
bony erosion than in those without [8]. RA joint
destruction is closely related to osteoclastogenesis and
the major inducer of OC, RANKL. So, we hypothesized
that MIF may play an important role in the process of
bone destruction in RA patients through the induction
of RANKL or direct involvement of osteoclastogenesis.
Thus we needed a greater understanding of the relation
between MIF and the pathogenesis of bony destruction
in RA. In this study, we determined the effect of MIF
on RANKL induction in human RA synovial fibroblasts,
the relation of RANKL and MIF, and the role of MIF in
OC differentiation in RA patients.
Materials and methods
Patients
Synovial fluids were obtained from 16 RA patients ful-
filling the 1987 revised criteria of the American College
of Rheumatology (formerly the American Rheumatism
Association) [15]. Informed consent was obtained from
all patients, and the experimental protocol was approved
by the Institutional Review Board for Human Research,
Konkuk University Hospital (KUH1010186). Synovial
tissues were isolated from eight RA patients (mean age
63.4 ± 4.6, range 38 to 76 years) undergoing total knee
replacement surgery.
Isolation of synovial fibroblasts
Synovial fibroblasts were isolated by enzymatic digestion
of synovial tissues obtained from RA patients undergoing
total joint replacement surgery, as described previously
[16].
Reagents
Recombinant human (rh) MIF, rhRANKL and rh mono-
cyte-colony stimulating factor (M-CSF) were purchased
from R&D Systems (Minneapolis, MN, USA). Partheno-
lide, curcurmin and cyclosporin A were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). LY294002,
SB203580, SP600125, PD98059, and AG490 were
obtained from Calbiochem (Schwalbach, Germany).
Anti-human IL-1b, TNF-a, IL-6, RANKL and MIF were
purchased from R&D Systems (Minneapolis, MN, USA).
Determination of concentrations of soluble RANKL and
MIF by sandwich ELISA
Concentrations of soluble (s) RANKL and MIF in sera
and synovial fluids were measured by sandwich ELISA
as described previously [16].
Immunohistochemistry of RA synovium and synovial
fibroblasts
Immunohistochemical staining for RANKL and MIF was
performed on sections of synovium. Briefly, synovium
samples were obtained from patients, fixed in 4% paraf-
ormaldehyde solution overnight at 4°C, dehydrated with
alcohol, washed, embedded in paraffin, and sectioned
into slices 7 μm thick. The sections were depleted of
endogenous peroxidase activity by adding methanolic
H2O2 and were blocked with normal serum for 30 min-
utes. After overnight incubation at 4°C with polyclonal
anti-human RANKL and anti-MIF antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), the samples
were incubated with the appropriate secondary antibo-
dies biotinylated anti-rabbit IgG or biotinylated anti-goat
IgG for 20 minutes and then incubated with streptavi-
din-peroxidase (Vector, Peterborough, UK) for one hour
followed by incubation with 3,3"-diaminobenzidine
(Dako, Glostrup, Denmark) for five minutes. The sec-
tions were counterstained with hematoxylin. Samples
were photographed with an Olympus photomicroscope
(Tokyo, Japan). Synovial fibroblasts were grown in 150
mm dishes in DMEM complete medium, plated at a
d e n s i t yo f1×1 0
4 cells/cm
2 onto glass coverslips (12
mm diameter), and stimulated with rhMIF (0.1, 1, 5,
and 10 ng/mL) (R&D Systems, Minneapolis, MN, USA).
Cells were fixed in 4% paraformaldehyde for immuno-
histochemical analysis using anti-RANKL antibody
72 hours after the addition of rhMIF.
Expression of RANKL mRNA measured by real-time
reverse transcription polymerase chain reaction
amplification
RA synovial fibroblasts were stimulated with rhMIF (0.1,
1, 5, and 10 ng/mL). For signal pathway analysis of
RANKL, synovial fibroblasts were incubated in the pre-
sence or absence of LY294002 (20 μM), SB203580
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(50 μM), cyclosporin A (100 nM), parthenolide (10 μM),
or curcumin (10 μM) for one hour before the addition
of rhMIF. After incubation for 72 hours, mRNA was
extracted using RNAzol B (Biotex Laboratories, Hous-
ton, TX, USA) according to the manufacturer’si n s t r u c -
tions. RT-PCR of 2 μg of total mRNA was carried out at
42°C using the SuperScript™ reverse transcription sys-
tem (Takara, Shiga, Japan). PCR was performed in a
20 μl final volume in capillary tubes in a LightCycler
instrument (Roche Diagnostics, Mannheim, Germany).
The reaction mixture contained 2 μl of LightCycler Fas-
tStart DNA MasterMix for SYBR
® Green I (Roche Diag-
nostics, Mannheim, Germany), 0.5 μM of each primer,
4m MM g C l 2, and 2 μl of template DNA. All capillaries
were sealed, centrifuged at 500 g for five seconds and
then amplified in a LightCycler instrument, with activa-
tion of polymerase (95°C for 10 minutes), followed by
45 cycles of 10 seconds at 95°C, 10 seconds at 60°C (for
b-actin control) and at 59°C (RANKL), and 10 seconds
at 72°C. The temperature transition rate was 20°C/sec-
ond for all steps. The double-stranded PCR product was
measured during the 72°C extension step by detection
of fluorescence associated with the binding of SYBR
Green I to the product. Fluorescence curves were ana-
lyzed with LightCycler software (v. 3.0; Roche Diagnos-
tics, Mannheim, Germany). The relative expression level
of each sample was calculated as the level of RANKL,
tartrate-resistant acid phosphatase (TRAP), cathepsin K,
calcitonin receptor, or MMP-9 normalized to the endo-
genously expressed housekeeping gene for b-actin. Melt-
ing curve analysis was performed immediately after the
amplification protocol under the following conditions: 0
s e c o n d s( h o l dt i m e )a t9 5 ° C ,1 5s e c o n d sa t7 1 ° C ,a n d0
seconds (hold time) at 95°C. The rate of temperature
change was 20°C/second, except for 0.1°C/second in the
final step. The melting peak generated represented the
amount of specific amplified product. The crossing
point (Cp) was defined as the maximum of the second
derivative from the fluorescence curve. Negative controls
were included and contained all elements of the reaction
mixture except template DNA. All samples were pro-
cessed in duplicate.
Western blot analysis
Synovial fibroblasts were incubated with rhMIF for
30 minutes, a whole cell lysate was prepared from about
2×1 0
5 cells by homogenization in the lysis buffer, and
the lysate was centrifuged at 14,000 rpm for 15 minutes.
The protein concentration in the supernatant was deter-
m i n e du s i n gt h eB r a d f o r dm e t h o d( B i o R a d ,H e r c u l e s ,
CA, USA). Protein samples were separated on 10% SDS-
PAGE and transferred to a nitrocellulose membrane
(Amersham Pharmacia Biotech, Uppsala, Sweden). For
western hybridization, the membrane was preincubated
with 0.5% skim milk in Tris-buffered saline (TBS) with
0.1% Tween 20 (TTBS) at room temperature for two
hours. The primary antibody to phospho-Akt, phospho-
STAT3, phospho-IBa, phospho-c-Jun (Cell Signaling
Technology Inc, Danvers, MA, USA) or phospho-p38
mitogen-activated protein kinase (MAPK; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) diluted
1:1000 in 5% bovine serum albumin, TTBS, was added
and incubated overnight at 4°C. The membrane was
washed four times with TTBS, horseradish peroxidase-
conjugated secondary antibody was added, and the
membrane was incubated for one hour at room tem-
perature. After TTBS washing, the hybridized bands
were detected using an ECL detection kit and Hyper-
film-ECL reagents (Amersham Pharmacia Biotech,
Uppsala, Sweden).
Monocyte isolation
Peripheral blood mononuclear cells (PBMC) were sepa-
rated by Ficoll-Hypaque (Sigma Chemicals, Poole, Dor-
set, UK) density gradient centrifugation from buffy coats
obtained from healthy volunteers. The cells were washed
three times with sterile phosphate-buffered saline (PBS)
and resuspended in RPMI 1640 (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS), 2 mM l-glutamine, and 1% penicil-
lin/streptomycin, henceforth called complete medium.
Freshly isolated PBMCs were incubated at 37°C in com-
plete medium and allowed to adhere for 45 minutes.
The nonadherent cells were removed and the adherent
cells were washed with sterile PBS, harvested with a
rubber policeman, and stained with monocyte-specific
anti-CD14 monoclonal antibody to assess the purity of
the preparation. Of the isolated cells, 90% expressed
CD14.
Osteoclast formation
RA synovial fibroblasts were seeded into 12-well multiwell
dishes (5 × 10
3 cells/well) and stimulated with rhMIF for
three days. As described above, isolated human monocytes
(5 × 10
4 cells/well) were added to the stimulated fibro-
blasts with fresh media. The cells were cocultured for
three weeks in a-minimal essential medium (MEM) and
10% heat-inactivated FBS in the presence of 25 ng/mL of
rhM-CSF. The medium was changed on day three and
then every other day. The addition of rhRANKL protein,
prepared as described previously [17], was used as a posi-
tive control. On day 21, TRAP-positive cells were identi-
fied using a leukocyte acid phosphatase kit according
to the manufacturer’s recommended protocol (Sigma-
Aldrich, Poole, Dorset, UK) [18].
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Data are expressed as the mean ± standard deviation
(SD). Statistical analysis was performed using the Mann-
Whitney U test for independent samples and the Wil-
coxon signed rank test for related samples. P values less
than 0.05 were considered significant.
Results
The relation between soluble RANKL and MIF in synovial
fluid of RA patients
The clinical characteristics of the 16 RA patients were as
follows: age 49.4 ± 2.5 years, disease duration 82.2 ±
12.4 months, erythrocyte sedimentation rate 42.7 ± 6.2
mm/h, and C-reactive protein 1.69 ± 0.3 mg/dL.
To determine the relation of MIF with sRANKL, the
concentrations of sRANKL and MIF in synovial fluid from
RA patients were measured using sandwich ELISA. In RA
patients, the synovial sRANKL concentration correlated
with the synovial MIF concentration in RA patients (g =
0.6; P < 0.001; Figure 1a), but the serum sRANKL concen-
tration did not correlate with serum MIF concentration
(g = 0.13; P = 0.5, data not shown). We used immunohis-
tochemical staining to compare the expression of MIF and
RANKL in synovial tissues. More intense staining of MIF
and RANKL was observed in synovium from patients with
RA compared with synovium from patients with osteoar-
thritis (OA). RANKL expression consistently overlapped
with that of MIF (Figure 1b).
Figure 1 The expression of MIF and RANKL in RA human synovial fluid and synovium. (a) Correlation between the levels of MIF and
sRANKL in synovial fluids from 16 patients with RA. (b) Immunohistochemical detection of MIF and RANKL in the synovium of patients with RA
and OA. All tissues were counterstained with hematoxylin (original magnification 400×). MIF, macrophage migration inhibitory factor; OA,
osteoarthritis; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor kappa-B ligand.
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human synovial fibroblasts
After RA synovial fibroblasts were stimulated with
rhMIF, the expression of RANKL mRNA and protein
was determined using real-time PCR, western blot, and
intracellular immunostaining. The expression of RANKL
mRNA and protein was increased in a dose-dependent
manner by rhMIF stimulation. The expression of
RANKL mRNA was maximal after stimulation with 5
ng/mL rhMIF at 72 hours (Figure 2a). There was a little
difference in the expression of RANKL protein which
was maximal with 10 ng/mL of rhMIF (Figure 2b).
RANKL expression also increased in the cultured RA
synovial fibroblasts, as shown by in vitro cellular immu-
nostaining 72 hours after MIF stimulation, with a simi-
l a rd o s er e s p o n s et ot h a td e m o n s t r a t e db yr e a l - t i m e
PCR (Figure 2c). There was neither a cytotoxic effect
nor a proliferative effect on RA synovial fibroblasts at
the experimental doses of rhMIF (data not shown).
There was no additive effect on RANKL expression
after stimulation with combinations of rhMIF and other
c y t o k i n e ss u c ha sT N F - a,I L - 1 b,a n ds t r o m a lc e l l -
derived factor (SDF)-1 (data not shown). After blocking
IL-1b, MIF-induced RANKL expression was partially
decreased, but the blockage of TNF-a or IL-6 had no
influence on MIF-induced RANKL expression (Figure
2d). As MIF-induced RANKL expression was decreased
after IL-1b inhibition, we examined the effect of MIF on
IL-1b expression in RA synovial fibroblasts. MIF also sti-
mulated IL-1b mRNA expression and the effect was also
maximal in a dose of 5 ng/ml at 72 hours (Figure 2e).
Intracellular signals involved in MIF-induced RANKL
expression in RA human synovial fibroblasts
To determine the signal transduction pathways mediat-
ing the MIF induction of RANKL expression, we used
20 μM LY294002 as a phosphatidylinositol (PI)-3
kinase inhibitor, 10 μM SB203580 as a p38 MAPK
inhibitor, 1 μM SP600125 as a c-Jun N-terminal kinase
(JNK) inhibitor, 10 μM PD98059 as a MAP kinase
kinase-1 (MEK1) inhibitor, 50 μM AG490 as a Janus
kinase 2 (JAK-2) inhibitor, 100 nM cyclosporin A as a
calcineurin inhibitor, 10 μMp a r t h e n o l i d ea saN F - B
inhibitor, and 10 μM curcurmin as an activator protein
(AP)-1 antagonist. RA synovial fibroblasts were prein-
cubated for one hour in the presence of the different
signal inhibitors, and then stimulated using 5 ng/mL of
rhMIF for 72 hours for PCR and 30 minutes for wes-
tern blot, respectively. The expression of RANKL
mRNA was determined by real-time PCR. The expres-
sion of RANKL mRNA was completely blocked after
inhibiting the activities of PI3K, STAT3, and NF-B( P
< 0.005). The expression of RANKL mRNA was also
partially blocked after inhibition of p38 MAPK and
AP-1 (P < 0.05). In contrast, the inhibition of JNK,
ERK, and calcineurin activities had no effect on MIF-
induced RANKL expression (Figure 3a). Cytotoxic
effects on synovial fibroblasts of the chemical inhibi-
tors at experimental concentrations were not observed
(data not shown). MIF activates the phosphorylation of
Akt, p38 MAPK, STAT3, IBa,a n dc - J u ni nR As y n o -
vial fibroblasts. The activated forms of Akt, p38
MAPK, STAT3, IBa, and c-Jun were detected by wes-
tern blot analysis in RA synovial fibroblasts stimulated
with rhMIF. The ratio of phosphorylated molecules
and total proteins was calculated as 2.33, 1.69, 3.4,
2.88, and 21.6, respectively (Figure 3b).
MIF induces osteoclastogenesis through the upregulation
of RANKL expression by RA human synovial fibroblasts
PBMC can differentiate into TRAP-positive multinu-
cleated OCs in the presence of RANKL and M-CSF
[19-21]. Isolated human PBMC were cocultured with
MIF-prestimulated RA synovial fibroblasts in the pre-
sence of M-CSF, and then TRAP-positive multinucleated
cells were also differentiated (P < 0.005). When the
monocytes were cocultured with MIF-prestimulated RA
synovial fibroblasts in the presence of anti-RANKL anti-
bodies, OC formation was significantly decreased (P <
0.05, Figure 4a). Next, isolated PBMC were cultured with
MIF-stimulated RA synovial fibroblasts and different sig-
nal inhibitors. After signal inhibition using LY294002,
SB203580, AG490 (P <0 . 0 5 ) ,p a r t h e n o l i d e( P < 0.005),
and curcurmin differentiation into OCs was significantly
decreased (Figure 4b). The expression of other osteoclas-
togenic markers, such as RANK, cathepsin K, calcitonin
receptor (CTR) and MMP-9 was also determined by real-
time PCR. Their relative mRNA expression correlated
well with the counted number of TRAP positive OCs
(Figure 4c). Meanwhile, after monocytes and MIF-presti-
mulated RA synovial fibroblasts were cultured in the pre-
sence of anti-IL-1 antibody, the differentiation of TRAP-
positive OC was decreased (Figure 4d).
MIF induced osteoclastogenesis in human monocytes via
PI3K, p38 MAPK, NF-B, and AP-1 pathways
To evaluate whether MIF, like RANKL, has a role in the
differentiation of monocytes into OCs, human PBMC
were cultured with rhMIF and rhM-CSF. Under the
influence of MIF and M-CSF, TRAP-positive multinu-
cleated cells, such as OCs, differentiated from the
monocytes, but the effect of MIF seemed to be less than
the effect of RANKL (P < 0.05). When the monocytes
were cultured with various doses of rhMIF, OC forma-
tion was significantly increased in a dose-dependent
manner (Figure 5a). The expression of OC surface mar-
kers was also increased after treatment with rhMIF (Fig-
ure 5b).
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Page 5 of 13Figure 2 The effect of MIF on the expression of RANKL in RA human synovial fibroblasts. (a) Isolated RA synovial fibroblasts were
incubated with rhMIF (0.1 to 10 ng/mL) for 72 hours, and mRNA was extracted and measured using real-time PCR. (b) Isolated RA synovial
fibroblasts were incubated with rhMIF (0.1 to 10 ng/mL) for 72 hours, and protein was extracted and measured using western blot analysis. (c)
RA synovial fibroblasts were cultured with 0.1 to 10 ng/mL of rhMIF for 72 hours and stained with an anti-RANKL antibody (red) (original
magnification 400×). (d) Effect of neutralizing agents for known osteoclastogenic factors on MIF-induced RANKL expression. RA synovial
fibroblasts were treated with rhMIF 5 ng/mL for 72 hours in the presence or absence of anti-IL-1b, anti-TNF-a, or anti-IL-6. RANKL mRNA
expression was quantified using real-time PCR. (e) Isolated RA synovial fibroblasts were incubated with rhMIF (0.1 to 10 ng/mL) for 72 hours, and
MIF-induced IL-1b mRNA expression was measured using RT-PCR. The data represent the mean and standard deviation of three separate
experiments. *P < 0.05 and **P < 0.005. MIF, macrophage migration inhibitory factor; RA, rheumatoid arthritis; RANKL, receptor activator of
nuclear factor kappa-B ligand.
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MIF-induced OC differentiation, the isolated monocytes
were cultured with rhMIF and different signal inhibitors.
The adhesion of the monocytes and their differentiation
into TRAP-positive OCs was significantly decreased
after culture with LY294002, parthenolide, curcurmin (P
< 0.05), and SB203580 (P < 0.005; Figure 5c). The
expression of OC surface markers was also decreased
after treatment of LY294002, SB203580, parthenolide,
and curcumin (P < 0.05; Figure 5d).
After inhibition of IL-1b, differentiation into OC was
decreased and the size of nucleus was also decreased
(Figure 5e).
Discussion
Synovitis and bony destruction are pathophysiological
characteristics of RA, and marginal bony erosion, periar-
ticular osteopenia, and joint space narrowing are the
radiographic hallmarks of RA [22,23]. Synovial inflam-
mation and bony destruction are closely related
Figure 3 Effect of signal inhibitors on MIF-induced RANKL expression in RA human synovial fibroblasts. RA synovial fibroblasts were
pretreated with 20 μM LY294002, 10 μM SB203580, 1 μM SP600125, 10 μM PD98059, 50 μM AG490, 100 nM cyclosporin A, 10 μM parthenolide,
or 10 μM of curcurmin, then cultured with 5 ng/mL of rhMIF for 72 hours. (a) After RA synovial fibroblasts were incubated with the signal
inhibitors and rhMIF, mRNA was extracted and measured using real-time PCR. The data represent the mean and standard deviation of five
separate experiments. (b) MIF activates the phosphorylation of Akt, p38 MAPK, STAT3, IBa, and c-Jun in RA synovial fibroblasts. The activated
forms of Akt, p38 MAPK, STAT3, IBa, and c-Jun were detected by western blot analysis in RA synovial fibroblasts stimulated with rhMIF, while
the amounts of total Akt, p38 MAPK, STAT3, IBa, and c-Jun were unchanged. The data represent one of three independent experiments. *P <
0.05 and **P < 0.005. MIF, macrophage migration inhibitory factor; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor kappa-B
ligand.
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Page 7 of 13Figure 4 Cocultures of monocytes and MIF-activated RA human synovial fibroblasts showed significantly more TRAP-positive
multinucleated cells. (a) Schematics for cocultures of isolated human monocytes and RA synovial fibroblasts prestimulated with rhMIF for OC
differentiation. RA synovial fibroblasts were pretreated with rhMIF 5 ng/mL for three days, monocytes were added to each well, and cocultures
were maintained in a-MEM containing 10% horse serum and 25 ng/mL M-CSF for 21 days. TRAP-positive multinucleated cells were counted.
Results are presented as the mean and standard deviation (SD) of four separate experiments. #P < 0.05 and **P < 0.005. (b) Schematics of
cocultures of isolated human monocytes and RA synovial fibroblasts prestimulated by rhMIF with or without signal inhibitors for OC
differentiation. RA synovial fibroblasts were pretreated with rhMIF 5 ng/mL for three days, monocytes were added to each well with the different
signal inhibitors, and cocultures were maintained in a-MEM containing 10% horse serum and 25 ng/mL M-CSF for 21 days. TRAP-positive
multinucleated cells were counted. Data represent the mean and SD of four separate experiments. *P < 0.05 and **P < 0.005. (c) The expression
of TRAP, RANK, cathepsin K, CTR, MMP-9, and b-actin mRNA from differentiated OCs that were cocultured with MIF-stimulated RA synovial
fibroblasts was measured using quantitative real-time PCR. (d) Differentiation into TRAP-positive multinucleated cells was decreased after
blocking of IL-1b.* * P < 0.005 versus monocyte + M-CSF + unstimulated RA FLS and P < 0.005 versus monocyte + M-CSF + MIF stimulated RA
FLS. The data represent the mean and SD of four separate experiments. CTR, calcitonin receptor; FLS, fibroblast-like synoviocytes; MIF,
macrophage migration inhibitory factor; MMP, matrix metalloproteinases; OC, osteoclast; RA, rheumatoid arthritis; TRAP, tartrate resistant acid
phosphatase.
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Page 8 of 13Figure 5 Human OC differentiation induced by MIF. (a) Schematics for OC differentiation after isolated human PBMC were cultured with 25
ng/mL of M-CSF and 100 ng/mL of rhRANKL or 0.1, 1, 5, 25 ng/mL of rhMIF. TRAP-positive multinucleated cells were counted. Results are
presented as the mean and standard deviation (SD) of four separate experiments. (b) The expression of TRAP, RANK, cathepsin K, CTR, MMP-9 by
the differentiated OCs was measured using quantitative real-time PCR. Data represent the mean and SD of four separate experiments. (c)
Schematics for OC differentiation after isolated human monocytes were cultured with 25 ng/mL M-CSF and 5 ng/mL rhMIF with 20 μM
LY294002, 10 μM SB203580, 50 μM AG490, 10 μM parthenolide, or 10 μM curcurmin. TRAP-positive multinucleated cells were counted. Data
represent the mean and SD of four separate experiments. (d) The expression of TRAP, RANK, cathepsin K, CTR, MMP-9 by the differentiated OCs
that were cultured with rhMIF was measured using quantitative real-time PCR. *P < 0.05 and **P < 0.005. (e) Differentiation into TRAP-positive
multinucleated cells was decreased after blocking of IL-1b.* * P < 0.005 versus M-CSF and
#P < 0.05 versus MIF 5ng/ml + M-CSF. Data represent
the mean and SD of four separate experiments. CTR, calcitonin receptor; MIF, macrophage migration inhibitory factor; MMP, matrix
metalloproteinases; OC, osteoclast; PBMC, peripheral blood mononuclear cell; RA, rheumatoid arthritis; RANKL, Receptor activator of nuclear factor
kappa-B ligand; TRAP, Tartrate resistant acid phosphatase.
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Page 9 of 13processes [24], but contrary to synovitis, the bony
changes are usually irreversible and accumulate with
time, and can bring about joint dysfunction and an
unfavorable disease outcome [25,26]. As a result, RA
causes significant socioeconomic impact because of phy-
sically disabled and unemployed people [27,28].
Both cellular mechanisms and various inflammatory
mediators are involved in the pathogenesis of bone ero-
sion in RA, forming complex networks [24,29]. Among
these process, OCs are the essential cells involved in the
cellular mechanisms of the process of bony erosion
[30-32]. In RA synovium, OCs are found at the pannus-
bone and pannus-subchondral bone junctions of
arthritic joints, forming erosive pits in the bone [30,31].
Two additional cells play important roles in osteoclasto-
genesis: synovial fibroblasts and activated T cells. They
express RANKL in the inflamed synovium, which pro-
motes osteoclastogenesis, and also express cathepsin K
at sites of synovial bone destruction [33]. RANKL is the
key molecule in OC differentiation and the augmenta-
tion of activity and survival of these cells, and is often
called OC differentiation factor (ODF). In the serum
transfer model of arthritis in the RANKL knockout
mouse, the synovial inflammation and cartilage erosions
are similar to those in wild-type mice, but the degree of
bony erosion is significantly reduced [34]. This result
confirms the essential role of RANKL in the pathogen-
esis of bone erosion, regardless of inflammation or carti-
lage damage. The expression of RANKL is regulated by
proinflammatory mediators such as TNF-a,I L - 1 ,I L - 6 ,
IL-17, and PGE2 [35]. These inflammatory molecules are
abundant in RA synovium, so the inflamed synovium
supplies an optimal environment for RANKL activation.
In this study, we determined the relation between
bony erosion and MIF in human RA. In the previous
studies, MIF induces TNF-a,I L - 1 ,I L - 6 ,a n dP G E 2,
which in turn promote RANKL expression [1,2,9,10,36],
and the synovial MIF concentration is higher in RA
patients with bony erosion than in those without [8].
Based on these results, we hypothesized that MIF might
have a role in the pathogenesis of bone erosion, that is,
it could have a direct effect on OC differentiation and
an indirect effect on the induction of other inflamma-
tory mediators that induce RANKL expression. First, we
measured the synovial concentrations of MIF and
RANKL in RA patients. Synovial fluid MIF concentra-
t i o nw a sh i g h e ri nR Ap a t i e n t st h a ni nc o n t r o l s ,a si n
our previous study [8], but the synovial RANKL concen-
tration did not differ between RA patients and controls.
In previous studies, serum and synovial RANKL levels
were higher in RA patients than in controls [37], but
the RANKL level was not related to any measures for
disease activity [38]. In contrast, we found that the
serum and synovial MIF concentration was well
correlated with RA disease activity [8,14]. Compared
with previous studies, the patients enrolled in this study
had longer disease duration and less active disease [37],
so MIF may reflect disease activity more closely than
does RANKL. In this study, synovial RANKL concentra-
tion was significantly correlated with synovial MIF con-
centration, and this observation led us to investigate
their close relation in the RA synovial tissues.
We investigated the effect of MIF on RANKL expres-
sion in RA synovial fibroblasts. Synovial fibroblasts, such
as activated T cells, are major sources of the RANKL
that promotes OC differentiation and bone erosion [33].
Like other proinflammatory cytokines, MIF stimulates
the expression of RANKL mRNA and protein in RA
synovial fibroblasts, but there was no additive effect
with other proinflammatory cytokines such as TNF-a
and IL-1b. After blocking IL-1b,M I F - i n d u c e dR A N K L
expression was partially decreased. This result suggests
that RANKL expression was directly induced by MIF
and also that it was indirectly stimulated by MIF-
induced IL-1b. IL-1b has the potential to induce OC dif-
ferentiation and RANKL expression, and overexpressed
MIF could induce some inflammatory mediators, such
as IL-1b in RA synovium, resulting in upregulation of
RANKL and promotion of OC differentiation. Therefore,
the MIF-IL-1b-RANKL interaction could be a major axis
involved in RA bone erosion.
We investigated the effect of MIF on OC differentia-
tion. We substituted MIF for RANKL in the traditional
culture system for OC differentiation. After isolated
PBMC were cultured with rhMIF and M-CSF, the num-
bers of TRAP-positive multinucleated cells were counted.
OC developed in this new system without RANKL, but
the degree of OC differentiation by MIF was less than
that of RANKL. This result showed that MIF is one of
the inflammatory cytokines involved in osteoclastogen-
esis, even if RANKL is the major molecule that induces
OC differentiation. We also demonstrated that MIF-pres-
timulated RA synovial fibroblasts have a potential effect
on osteoclastogenesis when the cells are co-cultured with
PBMC. This culture system is more practical in an in
vitro system similar to human RA synovium. RA synovial
fibroblasts are exposed to a variety of cytokines that pro-
mote inflammation, and when these ailing cells encoun-
ter OC precursors, they could induce osteoclastogenesis
by cytokine production or direct interaction between
cells. This study was focused on the indirect osteoclasto-
genic effect mediated by RA synovial fibroblasts and
RANKL, but MIF could directly enhance osteoclastogen-
esis from monocytes in the absence of additional
RANKL. These two pathways imply more distinct and
reinforced mechanisms for MIF-induced osteoclastogen-
esis, and a tipping point such as MIF production could
be a potential therapeutic target.
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MIF inhibits osteoclastogenesis [13]. Although MIF
enhances the expression of RANKL mRNA in murine
osteoblasts and the expression of RANKL mRNA is
enhanced in MIF transgenic mice, MIF inhibits OC for-
mation in bone marrow cultures by decreasing fusion
and decreasing the number of nuclei. The number of
TRAP-positive OC is greater in MIF-deficient mice than
in wild type mice, and the addition of MIF to the cells
decreased TRAP-positive OC formation. Therefore, it
appears that MIF plays an inhibitory role in bone resorp-
tion. The discrepancy between two studies could be
explained by several differences in study systems. First,
our study used human PBMC, whereas the former study
used osteoclast precursor cells from MIF knockout mice.
MIF inhibits osteoclast formation in vitro in wild type
mice bone marrow cell cultures and in the RAW264.7
macrophage cell line. Based on these data, MIF appears
to directly inhibit osteoclastogenesis in vitro but its effects
on osteoclasts in vivo are complex and may result from
decreased RANKL expression in the osteoclast precursor
cells from MIF knockout mice that were exposed to low
levels of RANKL in vivo and as a result these cells have
increased sensitivity to RANKL in vitro when cultured at
high density.The MIF knockout mice that they used, had
a marked resistance to lipopolysaccharide-induced endo-
toxic shock, and decreased TNFa production in response
to lipopolysaccharide treatment. TNF-a also acts directly
on the osteoclast precursor to potentiate RANKL-induced
osteoclastogenesis, even in the absence of elevated levels
of RANKL. MIF knockout mice were used in the pre-
vious paper, and had inhibited TNF production. Thus,
osteoclast formation may have been inhibited. Second, we
put the focus on an actual inflammatory disease of
humans. In human RA synovial fibroblasts, the over-
expressed MIF induces other inflammatory mediators,
and then the inflammatory mediators, such as RANKL
and IL-1b, enhance and potentiate osteoclastogenesis.
Third, the former study treated RANKL with MIF in the
OC differentiation system, but we did not treat RANKL
in the culture system. More intensive study will be
needed for explaining these conflicting results. We
hypothesize that MIF might play an essential role in nor-
mal bone remodeling; however, over-expressed MIF
might have an osteoclastogenic effect on bone metabo-
lism in inflammatory diseases.
We found that MIF-induced RANKL expression in RA
synovial fibroblasts was decreased by inhibition of NF-
B, PI3K, STAT3, AP-1, and p38 MAPK, but not ERK
and calcineurin. Of the three MAP kinase pathways,
only p38 MAPK was involved in MIF-induced RANKL
production. In addition, MIF-induced osteoclastogenesis
was suppressed by inhibition of NF-B, PI3K, AP-1, and
p38 MAPK, but not by inhibition of JAK/STAT3. These
results suggest that there are different signal pathways
involved in MIF-induced osteoclastogenesis. Considering
that AP-1 is a downstream molecule, MIF seems to
induce RANKL production by synovial fibroblasts
mainly via NF-B, PI3K, STAT3, and p38 MAPK, while
it promotes OC differentiation from monocyte precur-
sors via NF-B, PI3K, and p38 MAPK. In recent years,
numerous studies have attempted to define the signal
transduction pathways of inflammatory cells activated by
MIF in RA synovial fluid. MIF promotes cyclooxygen-
ase-2, PGE2, and IL-6 expression via p38 MAPK [39].
MIF also upregulates IL-8 and IL-1b via tyrosine kinase-
, protein kinase C (PKC)-, AP-1-, and NF-B-dependent
pathways [40]. MIF controls the proliferation of RA
synovial fibroblasts, mediated by ERK [36]. The upregu-
lation of MMP-2 by MIF is dependent on PKC, JNK,
and Src signal pathways [4]. MIF also upregulates other
MMPs including MMP-1 and MMP-3 via tyrosine
kinase-, PKC-, and AP-1-dependent pathways [6].
Through the various intracellular signal transduction
pathways, MIF activates RA synovial fibroblasts to pro-
mote inflammation, cartilage degradation, and bony
destruction. In our previous study, we found the induc-
tion of MIF is mediated by p38 MAPK pathway when
RA synovial fibroblasts are stimulated by conA, IFN-g,
CD40 ligand, IL-15, TGF-b, as well as IL-1b and TNF-a
[41]. Among these data, intracellular signal pathways are
deeply involved in the pathogenesis of RA. Clinical stu-
dies for RA treatment using the inhibitors of different
signal pathways such as Syk, p38 MAP, and JAK have
been performed until now, and successful results are
expected [42-44]. Beyond the inhibition of cytokines or
immune cells, oral inhibitors of intracellular molecules
will be another choice for refractory RA.
Conclusions
RA synovial fibroblasts were activated by MIF to pro-
duce RANKL, which is mediated by IL-1b,a n dt op r o -
mote osteoclastogenesis, which is mediated by RANKL
via pathways involving PI3K, p38 MAPK, NF-Ba n d
AP-1. The results add to expand our understanding of
t h er o l eo fM I Fi nt h ep a t h o g e n e s i so fb o n ee r o s i o ni n
human RA, and provide an experimental basis for the
development of anti-cytokine agents or target molecules
to block intracellular signal pathways in patients who
are at high risk of bone destruction or who do not
respond to conventional therapy.
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